Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Schlom Website

Jeffrey Schlom, Ph.D.

Selected Publications

1)  Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton DH, Huang B, Tucker JA, Tsang KY, Schlom J, Palena C.
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.
Clin Cancer Res. 18: 3868-79, 2012.
2)  Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Cancer Immunol. Immunother. 59: 663-74, 2010.
3)  Gulley JL, Madan RA, Tsang KY, Jochems C, Marte JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J.
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
Cancer Immunol Res. 2: 133-141, 2013.
Full Text Article. [Journal]
4)  Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Cancer Immunol. Immunother. 63: 407-18, 2014.
5)  Schlom J.
Therapeutic cancer vaccines: current status and moving forward.
J. Natl. Cancer Inst. 104: 599-613, 2012.
6)  Fallon J, Tighe R, Kradjian G, Guzman W, Bernhardt A, Neuteboom B, Lan Y, Sabzevari H, Schlom J, Greiner JW.
The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Oncotarget. [Epub ahead of print], 2014.
7)  Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, Schlom J, Hodge JW.
Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process.
Cancer Res. 74: 1945-57, 2014.
8)  Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
J. Clin. Oncol. 28: 1099-105, 2010.
9)  Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang K.
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
Cancer Immunol. Immunother. 63: 161-74, 2014.
10)  Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F.
Effects of conventional therapeutic interventions on the number and function of regulatory T cells.
Oncoimmunology. 2: e27025, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 6/20/2014.